KIR3DL1 and hepatocellular carcinoma: We then evaluated the influence of KIR-HLA combinations on HCC development in younger patients and witnessed the combinations of KIR2DL2-HLA-C1 and KIR2DS2-HLA-C1 to be significantly associated with younger HCC patients versus older patients (28.8% versus 12.3%; P = 0.008; OR = 2.89 and 25.0% versus 10.7%; P = 0.015; OR = 2.79, respectively).